These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 4108891)

  • 21. [Susceptibility of drug-resistant tubercle bacilli isolated from pulmonary tuberculosis in patients to paromomycin (Aminosidine) (author's transl)].
    Endo K
    Jpn J Antibiot; 1974 Apr; 27(2):141-3. PubMed ID: 4136451
    [No Abstract]   [Full Text] [Related]  

  • 22. Localization of co-resistance to streptomycin, kanamycin, capreomycin, and tuberactinomycin in core particles derived from ribosomes of viomycin-resistant Mycobacterium smegmatis.
    Yamada T; Mizuguchi Y; Suga K
    J Antibiot (Tokyo); 1976 Oct; 29(10):1124-6. PubMed ID: 62857
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cross-resistance relationship among capreomycin, kanamycin, viomycin and streptomycin resistance of Mycobacterium tuberculosis].
    Tsukamura M; Toyama H; Mizuno S; Tsukamura S
    Kekkaku; 1967 Oct; 42(10):399-404. PubMed ID: 4295935
    [No Abstract]   [Full Text] [Related]  

  • 24. [ACTIVITIES IN BLOOD OF SEVERAL ANTIMYCOBACTERIAL DRUGS DETERMINED BY THE SLIDE CELL CULTURE METHOD AS COMPARED WITH IN VITRO ACTIVITIES. I. CONCERNING STREPTOMYCIN, KANAMYCIN, CAPREOMYCIN AND VIOMYCIN].
    NAGATA A; MATSUMOTO M; MASE M
    Kekkaku; 1965 Jan; 40():6-11. PubMed ID: 14288531
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin.
    Akbergenov R; Shcherbakov D; Matt T; Duscha S; Meyer M; Wilson DN; Böttger EC
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4712-7. PubMed ID: 21768509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Distribution of the range of natural sensitivity to antitubercular preparations in cultures of strains of mycobacterum BCG].
    Kulikova MF
    Antibiotiki; 1968 Jul; 13(7):642-7. PubMed ID: 4301383
    [No Abstract]   [Full Text] [Related]  

  • 28. Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1962 to 1970: a national survey.
    Canetti G; Gay P; Le Lirzin M
    Tubercle; 1972 Jun; 53(2):57-83. PubMed ID: 4114335
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effectiveness of the drugs of streptomycin group in experimental studies on albino mice infected with Mycobacterium tuberculosis resistant to these drugs].
    Kozulitsyna TI; Kozlova NV
    Probl Tuberk; 1976 Sep; (9):70-4. PubMed ID: 64981
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cross-resistance of tubercle bacilli (a review) (III) (author's transl)].
    Tsukamura M
    Kekkaku; 1977 Apr; 52(4):171-5. PubMed ID: 69737
    [No Abstract]   [Full Text] [Related]  

  • 31. [Drug resistance of tubercle bacilli -- from the clinical point of view (author's transl)].
    Fukuhara Y
    Kekkaku; 1976 Dec; 51(12):477-87. PubMed ID: 65494
    [No Abstract]   [Full Text] [Related]  

  • 32. [Experimental and clinical study test of capreomycin].
    Kozlova NV; Dzhumaev B; Stepanian ES; Kaminskaia GO
    Antibiotiki; 1976 Jul; 21(7):650-4. PubMed ID: 60080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug resistance in Mycobacteria (author's transl)].
    Yamada T; Masuda K
    Kekkaku; 1976 Oct; 51(10):399-406. PubMed ID: 64637
    [No Abstract]   [Full Text] [Related]  

  • 34. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.
    Toungoussova OS; Mariandyshev AO; Bjune G; Caugant DA; Sandven P
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):202-6. PubMed ID: 15742171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interactions of antitubercular drugs. II. Combined effects of rifampin, ethambutol, capreomycin, viomycin, ethionamide and cycloserine on mycobacterial growth in vitro].
    Janowiec M; Zwolska-Kwiek Z
    Pneumonol Pol; 1983 Dec; 51(12):607-12. PubMed ID: 6199778
    [No Abstract]   [Full Text] [Related]  

  • 36. Capreomycin laboratory studies.
    Bloom C
    Antibiot Chemother; 1970; 16():1-9. PubMed ID: 4108887
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
    Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
    J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amikacin in the treatment of pulmonary tuberculosis.
    Allen BW; Mitchison DA; Chan YC; Yew WW; Allan WG; Girling DJ
    Tubercle; 1983 Jun; 64(2):111-8. PubMed ID: 6193623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Paper disk methods for determination of the drug sensitivity of Mycobacterium tuberculosis to the 2d order preparations. II].
    Afanas'eva IuP; Dorozhkova IR
    Lab Delo; 1969; 5():296-8. PubMed ID: 4185263
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system.
    Taniguchi H; Chang B; Abe C; Nikaido Y; Mizuguchi Y; Yoshida SI
    J Bacteriol; 1997 Aug; 179(15):4795-801. PubMed ID: 9244267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.